1	Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA
2	administration elicits potent and protective HIV-specific immune responses

- 3
- 4 Khamis Tomusange<sup>1</sup>, Danushka Wijesundara<sup>1</sup>, Jason Gummow<sup>1</sup>, Steve Wesselingh<sup>2</sup>, Andreas

5 Si	uhrbier <sup>3</sup> .	Eric J.	Gowans <sup>1</sup>	and Branka	Grubor-]	Bauk <sup>1#</sup>
------	------------------------	---------	---------------------	------------	----------	--------------------

- <sup>6</sup> <sup>1</sup>Virology Laboratory, Basil Hetzel Institute, Discipline of Surgery, University of Adelaide,
- 7 Adelaide, South Australia, Australia.
- 8 <sup>2</sup>South Australian Health and Medical Research Institute, Adelaide, South Australia,
- 9 Australia
- <sup>3</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia



12

Supplementary Fig S1. rHRV-DNA vaccination elicits superior Gag-specific effector 13 memory CMI in the spleen. Mice were vaccinated as described in the legend to figure 1 and 14 splenocytes harvested 14 days after the last dose. Splenocytes were stimulated for 1 h with 5 15 16 µg/ml of the H-2K<sup>d</sup>-restricted Gag<sub>197-205</sub> immuno-dominant in the presence of protein transport inhibitor (Brefeldin A, eBiosciences) for a further 6h.Cytokine production was analyzed by flow 17 cytometry. We gated on memory CD8<sup>+</sup> T cells to assess the number of CD44<sup>hi</sup>CD8<sup>+</sup> T cells 18 19 producing (A) IFN- $\gamma$ , (B) TNF- $\alpha$ , (C) IL-2, (D) IFN- $\gamma$  and TNF- $\alpha$ , (E) IFN- $\gamma$  and IL-2, (F) TNF- $\alpha$  and IL-2 and (G) IFN- $\gamma$ , TNF- $\alpha$  and IL-2 after stimulation. The data are representative 20 of 2 independent experiments, plotted as mean  $(n = 7) \pm SEM$  and each symbol represents an 21 individual mouse. \*  $p \le 0.05$ , \*\*  $p \le 0.01$ , \*\*\*  $p \le 0.001$  and <sup>ns</sup> p > 0.05 (Mann–Whitney U 22 23 test).



24

rHRV-DNA

Supplementary Fig S2. rHRV-DNA vaccination elicits a robust Gag-specific effector 25 memory CMI at the gut mucosa. Mice were vaccinated as described in the legend to figure 26 1 and lymphocytes from mesenteric lymph nodes harvested 14 days after the final dose. The 27 lymphocytes were stimulated for 1 h with 5 µg/ml of the H-2K<sup>d</sup>-restricted Gag<sub>197-205</sub> immuno-28 dominant peptide in the presence of Brefeldin A for a further 6 h.Cytokine production was 29 analyzed by flow cytometry. We gated on memory CD8<sup>+</sup> T cells to assess the number of 30 CD44<sup>hi</sup>CD8<sup>+</sup> T cells producing (A) IFN- $\gamma$ , (B) TNF- $\alpha$ , (C) IL-2, (D) IFN- $\gamma$  and TNF- $\alpha$ , 31 (E)TNF- $\alpha$  and IL-2, (F) IFN- $\gamma$  and IL-2and (G) IFN- $\gamma$ , TNF- $\alpha$  and IL-2 after stimulation. The 32 data are representative of 2 independent experiments and are plotted as mean  $(n = 7) \pm SEM$ 33 and each symbol represents an individual mouse. \*  $p \le 0.05$  and \*\*  $p \le 0.01$  (Mann–Whitney 34 35 U test).



Supplementary Fig S3. Gating strategy used to detect polyfunctional CD8<sup>+</sup>T cells in the
spleen. Mice were vaccinated as described in the legend to figure 1 and lymphocytes from
mesenteric lymph nodes harvested 14 days after the final dose. Cytokine profiles were
determined using flow cytometry. Splenocytes were gated on the lymphocyte population,
followed by doublet discrimination, and then gated on CD8<sup>+</sup> T cells to assess the frequency
of IFN-γ, TNF-α and IL-2. Representative plots for IFN-γ, TNF-α and IL-2 positive cells are
shown.



Supplementary Fig S4. Gating strategy used to detect polyfunctional CD8<sup>+</sup>T cells in the gut. Mice were vaccinated as described in the legend to figure 1 and lymphocytes from mesenteric lymph nodes harvested 14 days after the final dose. Mesenteric lymphocytes were gated on the lymphocyte population, followed by doublet discrimination, and then gated on  $CD8^+$  T cells to assess the frequency of IFN- $\gamma$ , TNF- $\alpha$  and IL-2. Representative plots for IFN- $\gamma$ , TNF- $\alpha$  and IL-2 positive cells are shown.

52



Supplementary Fig S5. Gating strategy used to detect polyfunctional effector memory
CD8<sup>+</sup>T cells in the spleen. Mice were vaccinated as described in the legend to figure 1 and
lymphocytes from mesenteric lymph nodes harvested 14 days after the final dose.
Splenocytes were gated on the lymphocyte population, followed by doublet discrimination,
and then gated on CD44<sup>hi</sup>CD8<sup>+</sup>T cells to assess the frequency of IFN-γ, TNF-α and IL-2.
Representative plots for IFN-γ, TNF-α and IL-2 positive cells are shown.



61 Supplementary Fig S6. Gating strategy used to detect polyfunctional effector memory

CD8<sup>+</sup>T cells in the spleen. Mice were vaccinated as described in the legend to figure 1 and
lymphocytes from mesenteric lymph nodes harvested 14 days after the final dose. Mesenteric
lymphocytes were gated on the lymphocyte population, followed by doublet discrimination,
and then gated on CD44<sup>hi</sup>CD8<sup>+</sup>T cells to assess the frequency of IFN-γ, TNF-α and IL-2.
Representative plots for IFN-γ, TNF-α and IL-2 positive cells are shown.



Supplementary Fig S7. Gating strategy to detect CD8<sup>+</sup> T cells in the spleen staining positive with the H-2K<sup>d</sup>-restricted Gag<sub>197-205</sub> peptide. Mice were vaccinated as described in the legend to figure 1 and lymphocytes from mesenteric lymph nodes harvested 14 days after the final dose. Splenocytes were gated on the lymphocyte population, followed by doublet discrimination, and then on H-2K<sup>d</sup>-restricted Gag<sub>197-205</sub> CD8<sup>+</sup>T<sup>+</sup>